Trial Profile
MicroRNAs Levels in Women With Postmenopausal Osteoporosis Under Antiresorptive or Osteoanabolic Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Teriparatide (Primary)
- Indications Osteoporosis
- Focus Pharmacodynamics
- Acronyms MiDeTe
- 25 Jan 2023 Status changed from active, no longer recruiting to completed.
- 19 Nov 2022 Results assessing circulating miRNAs as promising biomarkers for treatment monitoring in women with postmenopausal osteoporosis on denosumab (DMAB) therapy, published in the Journal of Clinical Endocrinology and Metabolism.
- 02 Oct 2021 Planned End Date changed from 30 Sep 2021 to 30 Sep 2022.